5-ala
Benign Neoplasms, Brain
Constantinos HadjipanayisSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Benign Neoplasms, Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rvp-001 Reveal Pharmaceuticals Inc. | Phase 2 | B |
Pioglitazone Wake Forest University Health Sciences | Phase 1 | CC |
Same molecule, other indications
5-ala is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →